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ulmonary Vein Stenosis Complicating Ablation
or Atrial Fibrillation
linical Spectrum and Interventional Considerations
avid R. Holmes, JR, MD, Kristi H. Monahan, RN, Douglas Packer, MD
ochester, Minnesota
blation procedures for atrial ﬁbrillation are being performed with increasing frequency. One of the
ost serious complications is the development of pulmonary vein stenosis, which occurs in 1% to 3%
f current series. The presentation of pulmonary vein stenosis varies widely. The majority of patients
re symptomatic although speciﬁc referral bias patterns can affect this. Symptoms may include dys-
nea or hemoptysis or may be consistent with bronchitis. These symptoms are affected by the number
f stenotic veins as well as the severity of the stenosis. The more severe the stenosis and the greater
umber of stenosed veins result in more symptoms. Because of the variability in symptoms, clinicians
ust have heightened sensitivity to the presence of the condition. Diagnostic tests of value include
agnetic resonance angiography and computed tomography. Although echocardiography has been
sed, it does not usually provide adequate assessment. Progression of stenosis is unpredictable and
ay be rapid. The speciﬁc anatomy of the stenosis varies widely and affects management. Because of
he presence of antral fusion of the origin of the left superior and left inferior pulmonary vein, a steno-
is involving 1 or the other can impinge and affect outcome. In this setting, bifurcation techniques fa-
iliar to interventional cardiology are very helpful. Controversy currently exists about the optimal
reatment approach. The use of balloons and larger stents (approximately 10 mm) results in more opti-
al results than just balloon angioplasty alone; however, even with stent implantation, recurrent reste-
osis may occur in 30% to 50% of patients. Follow-up of these patients typically involves computed
omography imaging to document restenosis. If signiﬁcant restenosis is identiﬁed, it should be treated
romptly because of the potential for progression to total occlusion. (J Am Coll Cardiol Intv 2009;2:
67–76) © 2009 by the American College of Cardiology Foundationa
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phe frequency of atrial fibrillation (AF) is increas-
ng; it is estimated that by 2010, approximately 2.6
illion people will be affected in the U.S.; by 2050,
hat number may increase to 10 million patients
1–3). Thromboembolic events, particularly stroke,
n older patients (2–4) are associated with AF.
Increasing information on anatomy and electro-
hysiology (5–7) has resulted in catheter mapping
nd surgical- or catheter-based ablation strategies
8–14) with targeted energy delivery to the left
rom the Department of Cardiovascular Diseases and Internal Medi-
ine, Mayo Clinic, Rochester, Minnesota.5
anuscript received September 16, 2008; revised manuscript received
ovember 11, 2008, accepted December 11, 2008.trial wall immediately outside of the pulmonary
ein (PV), proximal to the pulmonary veno-atrial
unction. Integrated datasets of anatomic (Fig. 1)
nd electrophysiologic information have been very
mportant (15–20). Imaging has documented an-
ral fusion of the left PV in more than 50% of
atients, which is important not only for ablation
trategies but also if PV stenosis occurs. Imaging
tudies have also documented the anatomic rela-
ionships between the PV, left atrial structures, the
nteratrial septum, the phrenic nerve, the esopha-
us, and the coronary arteries and characteristics of
eriadventitial tissue.
Current estimates are that upward of 40,000 to0,000 ablation procedures are attempted each year
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268n the U.S. Despite the improved information on the
natomic electrophysiologic factors leading to AF, ablation
as been limited by the complication of PV stenosis (PVS)
8,21–33). The underlying molecular mechanisms of PVS
emain poorly defined. One likely mechanism is intense
eriadventitial inflammation or collagen deposition, which
ay compromise or even occlude the lumen. This has been
ocumented by computed tomography (CT) with extensive
brosis in the perihilar PV tissues and the finding of a
ascade of inflammatory protein precursors in animal mod-
ls (33–37).
The frequency of PVS has varied substantially. An early
tudy (38) of patients in whom ablation had been performed
elatively deeply within the PV documented that 42.4% of
blated PV veins had stenosis. With improved experience
nd changes in procedural technique, the incidence has
allen. In worldwide center experiences collected from 188
enters, PVS occurred in 1.3% of cases (14). This decline
as been attributed to abandoning ablation within the PV,
he use of lower power ablation and intracardiac ultrasound
uidance, and image enhancements including CT or magnetic
resonance imaging for more ac-
curate delineation of the relevant
anatomy for ablation. As perfor-
mance of ablation procedures
migrates from tertiary care cen-
ters with experienced operators
to less experienced centers, the
prevalence may increase.
The location and severity of
the PVS varies. Although abla-
tion has been aimed at targeting
tissue either at or outside the
Figure 1. Right Upper and Lower Lobe PV
bbreviations
nd Acronyms
F  atrial fibrillation
T  computed tomography
V  pulmonary veins
VS  pulmonary vein
tenosis
IPV  right inferior
ulmonary veinComputed tomography images in (A) 2 views of the right superior pulmonary veins (PVV, the point of subsequent maximal PVS may occur from
he origin of the PV centrally out to 20 to 30 mm distant
rom the ostium. In several series (28,31), the pattern of
nvolvement is roughly 30% for right superior PV, left
uperior PV, and left inferior PV. The right inferior PV
RIPV) and right middle PV are infrequently involved. The
ength as well as the stenosis morphology and severity vary
onsiderably from short weblike lesions to long diffusely
iseased segments (Fig. 2).
In our original experience, the mean visual angiographic
tenosis at baseline was 80  13%, the mean trans-stenotic
radient was 12  5 mm Hg, and the typical stenosis was
ubular (31). The frequency of actual occlusion varies. Prieto
t al. (28) identified angiographic occlusion in 14 of 80 PV.
hen an occlusion is present, the possibility of restoring
dequate patency decreases markedly (33).
resentation
resentation varies (23,28,30,31,39) depending upon several
actors including: 1) the number of PV involved; 2) lesion
everity; 3) the response of the entire pulmonary vasculature to
he lesion; 4) the time course of stenosis; 5) clinical setting; and
) the presence and extent of collaterals. Some patients with
VS are asymptomatic. This however is a function of the
outine screening protocols used. If all patients undergoing
blation have routine follow-up CT imaging regardless of
ymptoms, the proportion of patients with asymptomatic PVS
ersus those with symptoms will vary.
Some patients with isolated mild PVS are asymptom-
tic, but patients with more extensive and severe involve-
ent may present with dyspnea, cough, chest pain,
emoptysis, or rarely an X-ray that is consistent with) and (B) 2 views of the right inferior PV documenting severe stenosis (arrows).
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269ronchitis or pneumonitis. Accordingly, a high index of
uspicion is required. Presentation with hemoptysis con-
ers immediacy to evaluation and treatment, but in our
xperience it typically responds to discontinuation of
nticoagulation alone.
Given the variability in clinical presentation, and often
typical findings, the diagnosis may be missed or the
ymptoms attributed to another illness such as broncho-
neumonia or interstitial lung disease. Routine screening
s well as enhanced surveillance for symptoms that may
erald the onset of PVS is extremely important. Given
he sometimes rapid progression of asymptomatic PVS
ithin 1 to 3 months of initial development, enhanced
urveillance early before the disease becomes manifest is
lso very important.
Symptom variability varies in part with regards to the
xtent, distribution, and severity of PVS. More severe
tenosis and a greater number of veins involved usually
esults in more symptoms (Fig. 3). In our initial experi-
nce (31) of 23 patients with stenosis of 34 PV, patients
ad developed symptoms over 103  100 days following
he index procedure; although some patients developed
ymptoms immediately. The most frequent symptom was
xertional dyspnea (n  19). Flulike symptoms were
oted by 3 patients, 3 patients had received a course of
ntibiotics for presumed bronchitis, and 3 presented with
Figure 2. Percutaneous Intervention
Although the severity and length of stenosis can vary, angiography usually
reveals long diffuse disease as seen in this left superior pulmonary vein
(LSPV).emoptysis.iagnosis of PVS
ssessment of the presence and degree of severity of PVS is
ssential. Although chest X-rays may be abnormal, they are
ot diagnostic. Ventilation/perfusion scans (39) can be used
o characterize the physiology of blood flow within the
istribution of a PVS. Under normal conditions, the appar-
nt blood flow of one-third of a lung ranges between 15%
nd 30%. With increasingly severe PVS, local perfusion
ecreases substantially, particularly with stenoses 65% to
5%. With severe stenosis, local blood flow within the
ffected PV can be decreased to as low as 3% to 4%.
Transesophageal echocardiography is limited by its in-
bility to image deeply into all 4 PV and is less useful in
stablishing the extent and location of PVS.
Currently, CT (Fig. 1) and to a lesser extent magnetic
esonance imaging provide the best tests for evaluation. In
ur initial series (31), the mean pre-stenotic PV orifice
imension of the PV, which subsequently stenosed, was
7.3 mm (range: 12 to 24 mm). The baseline vessel
iameter at the point of maximal stenosis was 3  2 mm.
he stenosis began approximately 1 to 2 mm distal to the
rifice, extending for variable lengths from 7 to 35 mm. An
mportant caveat was identified by Prieto et al. (28) in their
eries of 44 patients and 80 stenosed veins. Of these 80
eins, a CT was interpreted as showing complete occlusion
n 27; however, using subselective pulmonary artery angiog-
aphy, in 13 of the 27, a small lumen was identified. This
iscrepancy has important implications; the presence of an
cclusion reduces the success rate markedly.
nterventional Procedure
10- to 12-F venous sheath is placed for intracardiac
ltrasound imaging, a small 4-F arterial sheath for pressure
Figure 3. Impact of Stenosis Severity and Affected Vein Number on
Symptoms in Pulmonary Vein Stenosis
Symptoms emerged at 60% to 70% stenosis, particularly in patients with
more than 1 affected vein.
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270easurement and for facilitating transseptal puncture (using
pigtail catheter as a reference for the position of the aortic
alve), and a 7-F catheter for pulmonary atrial pressure
onitoring and the transseptal sheath. The transseptal
rocedure can also be performed relying on guidance with
nly intracardiac echocardiograph with observation of direct
ntry using saline injections through the needle.
Traditionally, a Mullins (Medtronic Vascular, Santa Rosa,
alifornia) sheath with a Brockenborough (Medtronic) needle
s used to cross the intra-atrial septum. However in our
xperience, a Mullins sheath complicates access into the right
uperior PV or RIPV. An SRO, SLO, or SL-1 (St. Jude
edical, Saint Paul, Minnesota) catheter is stiffer and more
aneuverable. Crossing at the level of the membranous fossa is
ptimal; if the puncture is too high or too posterior, access to
specific PV can be substantially more difficult. If the target
esion involves the RIPV, a more anterior septal puncture may
ake access easier. If the target is the left superior PV or left
nferior PV, a more posterior septal approach is better. A high
uncture can result in damage to the dome of the left atrium.
ue to the fact that these patients have already had 1 or more
ransseptal procedures, the intra-atrial septum may be thick-
ned and the transseptal needle may slide superior-cranially
ver the limbus resulting in a high puncture. In this setting, the
urve of the needle may need to be manually shaped. Steerable
heaths will offer great advantages and improve access to all of
he veins.
After left atrial entry, the sheath is fully aspirated and
ushed with heparinized saline to minimize air entrapment.
ntravenous heparin (5,000 U) is given and titrated with
epeated boluses to keep the activated clotting time at
pproximately 300 s. All 4 PV can be entered. Typically, a
-F A1 or A2 multipurpose catheter is used for entry into
ach vein. For some specific veins, for example, the RIPV,
ccess may require a change in the guiding sheath. Steerable
eflectable sheaths have made intubation of that specific PV
uch easier. In patients with a pre-procedural CT that has
ocumented a PV segment occlusion, angiography of the
eft atrium may document patency. In patients in whom a
pecific PV cannot be entered, it is helpful to interrogate the
eft atrium by intracardiac ultrasound to look for aliasing
olor flow from the veins, with or without increased flow
elocity. In addition, in some patients, a subselective pul-
onary arterial angiogram with delayed filming may allow
isualization of the veno-atrial junction.
After placement of the multipurpose catheter in the PVS,
trans-stenotic gradient is measured that varies depending
n lesion severity and length, but for significant stenosis, it
s usually 10 to 12 mm Hg. A hand contrast injection,
hrough the multipurpose catheter or the sheath, is used to
ocument the stenosis severity and length and the presence
f affected branches. During this time, intracardiac ultra-
ound is used to assess translesional velocity, which in our
xperience can be 1.0 to 1.6 m/s but with very severe tubtotal stenosis may be1.0 m/s (Fig. 4). The diameter of
he PV dictates in large part dilation strategy; if the PV is
ess than approximately 5 to 8 mm, long-term successful
atency is low. For larger veins, even if there is a severe
tenosis, long-term patency rates are improved. Angiogra-
hy in orthogonal view is crucial to identifying the presence
nd extent of collateralization and involvement of signifi-
ant side branches. Intracardiac ultrasound is also required
o that if a stent is to be used, it is placed optimally to cover
he lesion (Fig. 5A), to avoid side branches if possible, and
o avoid placement too proximal so that the stent protrudes
nto the left atrial body (Fig. 5B). For left PVS, if an antral
tenosis is present, bifurcation stenting techniques may be
equired, including kissing balloons placed through 2 sepa-
ate transseptal catheters or dilation and stenting through
he side of 1 stent (Figs. 6A to 6D).
If a significant lesion is present, as assessed by velocities,
ressure gradient, and angiography, treatment is initiated.
mage setup for treatment is important so that the periph-
ral extent of the lung field is visualized but also so that the
lane of the ostium is also well seen. We typically place a
ong exchange extra support 0.035-inch tight J-curved
uidewire in the peripheral pulmonary venous bed; it should
lways be visible because guidewire damage and/or perfora-
ion may cause catastrophic hemorrhage. We routinely
ilate with an 8- to 10-mm balloon. In our experience, the
se of a balloon 12 mm significantly increases the risk of
issection or rupture. The practice continues to evolve, and
t the present time if a stent is required, we usually stent
ith a 10-mm over-the-wire stent using a 10  18 mm or
0  29 mm balloon-mounted stent (Genesis, Cordis,
iami Lakes, Florida).
There are diverse opinions about the need to routinely
mplant stents both to optimize the initial and long-term
tent. Prieto et al. (28) found that success rate defined as a
esidual stenosis 30% was achieved with balloon dilation
lone in 42% of stenosed veins compared with 95% when
he vein was treated with stenting. As mentioned, if the
essel is very small, for example, only 4 to 5 mm, long-term
atency is uncommon. Not all centers routinely use stents as
he first line of therapy. In some centers, including our own,
f during the initial index procedure for PVS, dilation alone
esults in significant reduction or obliteration of the gradient
nd improvement in flow velocity, and less than approxi-
ately 20% residual stenosis, we do not place a stent. These
atients are followed carefully with CT studies; if restenosis
ccurs, then stent implantation is performed. Resolution of
he discrepancies between these 2 approaches will take
arger series and may involve a randomized study. In the
etting of restenotic lesions after initial dilation of PVS, we
outinely place stents if possible.
Following either dilation alone or stent deployment, the
alloon is removed, leaving behind the guidewire. Typically,
he gradient decreases to5 mm and velocity to1.5 m/s. In
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271ur experience (31), intervention reduces the stenosis to 9 
% and the gradient to 3  4 mm of mercury while the PV
elocity decreased to 1.1  0.2 m/s. If the result with dilation
s suboptimal, then a stent is placed. As previously mentioned,
e routinely stent all restenotic lesions if they have been treated
reviously with dilation alone. Following documentation of a
atisfactory result, the guidewire can be withdrawn under
uoroscopy guidance because the stiff wire can dislodge a
reshly placed stent. If other pulmonary veins are to be treated,
hey can now be approached.
pecial Circumstances
n some patients, the pre-procedural CT indicates that the
V is occluded. Typically this occlusion is ostial. In this
etting, left atrial angiography in the region of the ostium
ay reveal a dimple that can be probed with a stiffer wire to
ee if patency can be restored. Alternatively, subselective
psilateral pulmonary artery angiography can be performed
Figure 4. Impact of Intervention on Doppler Flow Patterns
Velocities measured at the time of intervention with improvement following sith delayed imaging to evaluate left atrial filling. If the vein ts occluded, even though the occlusion can be probed
uccessfully, maintenance of longer term patency is very
ncommon.
Di Biase et al. (33) reported on 18 patients with complete
cclusion of 1 PV. They found that patients with a single
cclusion are often asymptomatic, and that there is a strong
orrelation with involvement of other ipsilateral veins mea-
ured as an average cumulative stenosis of the vascular
ross-sectional area. Intervention was attempted in 17
atients and failed in 2. Of the remaining 15 patients,
ilation alone was attempted in 7 while the remaining
atients received a stent. The mean time to intervention
etween successful and failed groups was shorter in the
ormer patients. Restenosis rates were high in 46%.
In some patients, the PV has become small and appears
ery fibrotic as assessed with ultrasound or CT imaging. In
his setting, we usually dilate the vessel only and use a 4- to
-mm coronary balloon. Even though cutting balloons can
e used, there is only anecdotal information available as to
ful treatment.he effect on outcome. In our experience, if the PVS vessel
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272oes not accommodate a 10-mm stent, it is difficult to
chieve a long-lasting result even with a small drug-eluting
tent. We have also attempted oral sirolimus in an anecdotal
ase although no series is available.
A common antrum is frequent in the left lung. If both the
eft superior PV and left inferior PV have ostial stenoses,
ifurcation stenting approaches may be required. For this, 2
ransseptal sheaths and simultaneous stents are placed or a
econd stent can be placed through the side of the initial
tent. During this procedure as well as with the treatment of
ny ostial lesions, it is essential to completely cover the
esion but avoid placement that is too proximal, leaving the
tent extending into the body of the left atrium.
There are patients in whom the pre-treatment CT study
ocuments filling defects in the stenosed PV. In this setting,
hese filling defects may represent thrombus that could then
mbolize during procedural performance. Typically we more
Figure 5. Pulmonary Vein Stenosis Positioning and Encroachment
(A) Optimal stent position can be obtained with either intracardiac echocardio
deployment in the LSPV with protrusion into the body of the left atrium. Posit
cult. LA  left atrium; LIPV  left inferior pulmonary vein; RA  right atrium;losely optimize anticoagulant therapy with warfarin, aspi- hin, and clopidogrel before proceeding with the intervention
o try to prevent distal embolization.
Progression of severe PVS can be rapid; once a severe
tenosis is documented, the lesion should be treated promptly.
iven the potential for rapid progression, we adjust our
ollow-up schedule. If following the initial post-ablation CT
tudy, a stenosis of 50% to 70% is identified on a subsequent
T, then it is re-evaluated at 3 to 6 months. If the stenosis is
75%, CT is repeated in 3 months unless symptoms develop
ooner. Following dilation, the same rapid progression can be
een. If a stenosis is found to be approximately 90%, urgent
reatment is indicated because the lesion can progress to
cclusion within 3 to 6 weeks.
djunctive Therapy
rocedural. During the procedure, we give unfractionated
y or angiography. (B) Intracardiac ultrasound documents suboptimal stent
the stent suboptimally will make cannulation or treatment of the LIPV difﬁ-
right superior pulmonary vein; other abbreviations as in Figures 2 and 3.graph
ioningeparin and maintain an activated clotting time of 300 to
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27350 s. Typically, the initial bolus of heparin is not administered
ntil after an uncomplicated transseptal puncture is accomplished.
ost-procedural. Patients are maintained on full dose war-
arin to achieve an international normalized ratio of 2 to 3
ecause pulmonary arterial thrombosis in the distribution of
he affected PV has been documented. The optimal dura-
ion of warfarin therapy is unknown; from a clinical stand-
oint, we typically continue it indefinitely. This also relates
n part because the AF may recur. Sometimes aspirin and
lavix are added empirically.
ollow-Up
here is limited follow-up of patients treated for PVS
Table 1). In our initial series of 23 patients, all had
ubstantial reduction in symptoms, typically within the first
4 h of the procedure (31). However, 14 (57%) developed
ecurrent symptoms at a mean of 3.2 2.8 months after the
ndex intervention, and 13 of the 14 required repeat inter-
ention. After single or multiple reinterventions, at
ollow-up at 18  12 months, 15 patients were asymptom-
tic from the PV stenosis and 4 had mild and 3 had
oderate symptoms.
Prieto et al. (28) evaluated the specific role of stenting in
Figure 6. Treatment of Left PVS
(A) Right anterior oblique (RAO) view of stent in the LSPV. This resulted in com
(RAO) view. (C) A balloon is used to dilate the stent struts and a stent is delive
patency of both superior and inferior pulmonary veins but still residual ostial sheir population. They found that in those patients treated dith dilation alone, restenosis requiring repeat dilation
ccurred in 72% versus patients treated with stent implan-
ation in which restenosis requiring repeat intervention was
een in 33% (p  0.001). The time duration free from
estenosis was also significantly longer in patients treated
ith initial stenting. The relationship between stent size
nd outcome was also assessed. Those patients treated with
arger stents had significantly improved outcome compared
ith patients treated with smaller stents (hazard ratio for
tents 9 mm: 6.8, 95% confidence interval: 1.1 to 44.2;
 0.043) (28). As a whole, in their series, 22 of 34 (65%)
ere completely asymptomatic. There is lack of agreement
ithin the field however and rates vary substantially de-
ending on the follow-up protocol used and definition of
estenosis. In our experience (31,40), in-stent restenosis
ccurs in approximately 50% of veins and requires repeat
reatment.
Follow-up protocols vary. Typically, we perform CT the
ay after the index procedure to document initial baseline
mprovement. As previously discussed, rapid progression of
tenosis to occlusion has been documented. So if another
ein is found to have a severe stenosis, consideration should
e given to treating it. Prieto et al. (28) found that a shorter
ise of the LIPV. (B) A guidewire is placed through the side of the LSPV stent
the LIPV. (D) The LIPV is dilated. (E) The ﬁnal angiographic result with wide
is. Abbreviations as in Figures 2, 3, and 5.prom
red touration of time from initial documentation to first catheter
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274ntervention for stenosis is associated with improved out-
ome. They hypothesized that progressive atrophy of the
essel proximal to the stenosis impacts the ability to obtain
n optimal early and late result.
After the initial baseline post-intervention CT, follow-up
ncludes careful monitoring for recurrent symptoms with
rompt evaluation if symptoms recur (Fig. 7). Follow-up CT
ay also be performed even if the patient is asymptomatic,
lthough the radiation dose with CTmust be kept in mind. An
mportant consideration is the role of collaterals that may form
rom either ipsilateral or even contralateral veins. Extensive
ollaterals may explain the fact that some patients with severe
tenosis may be relatively asymptomatic. This is particularly the
ase with a stenosis of only 1 PV. If PVS involves multiple
eins, collateralization may be suboptimal.
Figure 7. Management of PV Stenosis
Approach to management of pulmonary vein (PV) stenosis depends on the co
Table 1. Follow-Up PVS Intervention
Study (Ref. #) Year PVS (Patients) PVS (Veins)
Saad et al. (23) 2003 21* NA
Packer et al. (31) 2005 23 34
Di Biase et al. (33) 2006 18† NA
Prieto et al. (28) 2007 34 55
Recurrence are high irrespective of whether stents are used or not although some authors (28) indi
*Severe stenosis 70%; †all complete occlusion.
BA balloon angioplasty; NA not available; PVS pulmonary vein stenosis.prior treatment. CT/MR  computed tomography/magnetic resonance; PCI  percutonclusions
trial fibrillation is the most common clinically important
ardiac arrhythmia and is increasing in frequency as the
opulation ages. Increasing information about the underly-
ng electrophysiologic/anatomic substrate has led to a grow-
ng experience with surgical and catheter ablation proce-
ures. Pulmonary vein stenosis as a result of catheter
blation occurs in 1% to 3% of patients even in experienced
enters. The presentation and clinical course of these
atients is very variable. Treatment of PVS involves both
natomic and physiologic considerations. Recurrent stenosis
s relatively frequent. Controversy exists about the role of
nitial stent placement versus provisional stenting. For
ecurrent stenoses, stenting is required.
tion of several factors including patient symptoms, severity of stenosis, and
Intervention Follow-Up
BA alone—17 veins
Stents—10 veins
Repeat intervention in 8 patients (47%)
BA alone—20 veins
Stents—14 veins
Repeat intervention in 13 patients
BA alone—7 patients
Stents—8 patients
Restenosis 13 of 28 patients (46%)
BA alone—39 veins
Stents—16 veins
Repeat intervention 28 of 39 BA alone, 33% stent
t treatment with a large stent may improve restenosis rates compared with dilation alone.mbinacate thaaneous coronary intervention; other abbreviations as in Figures 1 and 3.
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